Multiligand Nanoparticle Targeting Lymphoma Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RNAi therapeutics for cancer, such as siRNAs, face challenges with intravascular degradation, limited tissue penetrance, and nonspecific delivery, particularly in targeting non-Hodgkin's lymphoma cells, which are difficult to transfect and exhibit resistance to conventional treatments like rituximab.
Innovation Solution
A nanoparticle-based drug delivery system comprising a core with poly-L-lysine, a hyaluronic acid shell, and conjugated anti-CD20 and anti-CD19 or anti-CD22 antibodies, designed to specifically target lymphoma cells, enhancing biodistribution and internalization while using RNAi therapeutics to inhibit oncogene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If single-ligand-conjugated platforms are used for targeting, then the device complexity is reduced, but the targetability and internalization efficiency deteriorate due to receptor saturation
Solution Approach 1:
The targeting platform is segmented into multiple independent ligand types (anti-CD20 antibody and hyaluronic acid) conjugated to the nanoparticle surface. This segmentation allows simultaneous binding to different receptors (CD20 and CD44) on lymphoma cells, preventing receptor saturation and enhancing targetability without significantly increasing operational complexity
Solution Approach 2:
The nanoparticle platform is designed with multi-functionality by incorporating both anti-CD20 antibodies and hyaluronic acid ligands that target different receptors (CD20 and CD44). This universal targeting approach enables the platform to bind to multiple receptor types simultaneously, improving internalization efficiency while maintaining reasonable device complexity
2Ease of manufacture
If conventional transfection methods are used, then the ease of manufacture is maintained, but the delivery efficacy to lymphoma cells deteriorates due to difficulty of transfection
Solution Approach 1:
The nanoparticle uses a composite structure combining polymeric siRNA, poly-L-lysine, and hyaluronic acid. This composite material approach enables effective delivery to lymphoma cells by combining the gene-silencing capability of siRNA with the cell-targeting and transfection-enhancing properties of poly-L-lysine and hyaluronic acid, overcoming the limitations of conventional transfection methods
3Device complexity
If non-specific delivery is used, then the device complexity is reduced, but the harmful factors increase due to side effects on healthy cells
Solution Approach 1:
The nanoparticle surface is functionalized with specific targeting ligands (anti-CD20 antibody and hyaluronic acid) that provide local quality enhancement at the target site. These ligands enable selective binding to lymphoma cells expressing CD20 and CD44 receptors, concentrating the therapeutic effect locally while minimizing exposure and harmful effects on healthy cells
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves improved delivery and therapeutic efficacy by specifically targeting lymphoma cells, inhibiting proliferation, and demonstrating enhanced stability and physiological compatibility, potentially treating non-Hodgkin's lymphoma effectively.
Implementation Method 1
an anti-CD20 antibody conjugated to the surface of the shell; and an anti-CD19 antibody or anti-CD22 antibody conjugated to the surface of the shell
Implementation Method 2
a shell composed of hyaluronic acid layered on the surface of the core
Data Source
AI summary
Disclosed are a lymphoma cell-specific drug delivery system for the prevention or treatment of lymphoma and a production method therefor. The lymphoma cell-specific drug delivery system may be delivered into lymphoma cells in an improved manner compared to conventional single-target drug delivery systems, and is applicable to the delivery of various therapeutic drugs for the treatment of lymphoma through the application of a wide range of drugs and the same antibody functionalization strategy on the surface of different types of nanoparticles. In addition, the drug delivery system may be introduced into lymphoma as well as other cancer types by adjusting the type and mixing ratio of antibody, and may propose a method of introducing polymeric nucleic acid drugs having superior physiological stability and drug efficacy compared to conventional monomeric nucleic acid drugs, thereby enabling effective drug treatment of lymphoma which is highly resistant to intracellular drug delivery.